Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Saroja Pharma Industries India Ltd. (SAROJA)
SME CapPharma stocks · SME cap · NSE
Saroja Pharma Industries India Ltd. operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals11 Oct 2026 · screener
Latest result01 Jun, 07:57 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
74BullishSMA20 +22.9% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 58
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SAROJAD candles · FIT view+24.2%Latest close ₹40.80 on 2026-10-19
Bar
+0.0%
RSI
60
MACD hist
-0.03
52W pos
78%
2026-10-19O ₹40.80H ₹40.80L ₹40.80C ₹40.80Vol 1,600 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SAROJANifty PharmaNifty 500
- SAROJA
- +36.0%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +41.6 pp
Chart stats
19 Oct 2026- From 52W high
- -32.0%
- 52W range position
- 40%
- ATR (14)
- 3.7%
- Volume vs 20D
- 0.27x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹31.5 - ₹43.3
₹60
₹28 - ₹60
₹1.5
Latest completed session
20-session average
59.8% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · FAIR VALUE48
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +62.5% · PAT +173.7% YoY
Technical
Bullish74
Price trend and sector-relative-strength timing.
Valuation
Legacy model+77.3%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence68
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Excellent · 90/100Rev +63% YoY · PAT +174% YoY · margin expansion · operating leverage
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹31.5 Cr | +62.5% | -18.8% |
| EBITDA | ₹2.4 Cr | NDF | +77.4% |
| Operating margin | 7.7% | NDF | +419 bps |
| PAT | ₹1 Cr | +173.7% | +82.5% |
| PAT margin | 3.3% | NDF | +183 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 9.82
- P/B
- 0.95
- EV/EBITDA
- 7.86
- Market Cap
- 16.40Cr
Profitability
- ROE
- 10.10%
- ROCE
- 13.40%
- ROA
- 3.86%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 14.00%
- EPS 5Y
- 18.00%
- Revenue 3Y
- 12.00%
- EPS 3Y
- 16.00%
Balance Sheet
- Debt/Equity
- 0.83
- Interest Coverage
- 2.56×
- Altman Z
- 2.98
- Book Value
- 43.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- 7.44 Cr
- EPS TTM
- 4.00
Shareholding
- Promoter Hold
- 73.02%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 64%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 70.1+30.5% vs prev
Net Profit
₹ CrLatest: 1.6+56.3% vs prev
Return on Equity
%Latest: 9.3+41.7% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 60.
- SMA20 rising (~18.7% over last month) — short-term momentum positive.
- RSI(14) at 60 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 8% off 52W high · 46% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
65
RS percentile
Insufficient history
1M return
+33.8%
3M return
+22.3%
6M return
-12.8%
1Y return
-
RS 1D
-8
RS 20D
+52
Sector rank
#1
Industry rank
#11
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
price above
200-DMA
unavailable
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
104 observations
19 Oct 2026Value 96.21+0.14%
RS vs Nifty 50096
Valuation & peers
U-Score 48 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 48 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · FAIR VALUEValuation27/30
Growth16/25
Quality2/20
Balance Sheet7/15
Cash Flow1/10
Piotroski
6/9 (+3)
Penalties
-8
Raw sum
48
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
48/100 · legacy band FAIR VALUE
Positive drivers
- Fair-value margin of safety is positive at 77.3%.
- Valuation contributes 27/30 to the score.
- Growth contributes 16/25 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
9.8
PB
0.9
EV/EBITDA
7.9
ROE
10.1%
ROCE
13.4%
FCF Yield
—
Debt/Equity
0.8
MoS
+77.3%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
48
Previous: 48
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+77.3%
Previous: +77.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
48
48
48
48
48
48
48
48
48
48
48
48
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹62.21
+34.4% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹180
+77.3% MoS
PEG
0.57
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
LASA
Small
Lasa Supergenerics Limited
Pharmaceuticals
match 152
5
—
-19.7%
—
OVERVALUED
MEDIORG
SME
Medicamen Organics Ltd.
Pharmaceuticals
match 151
14
—
-13.8%
—
OVERVALUED
INFINIUM
SME
Infinium Pharmachem Ltd.
Pharmaceuticals
match 149
36
39.1
10.5%
+16%
WATCHLIST
BLUEJET
Large
Blue Jet Healthcare Limited
Pharmaceuticals
match 143
38
69.9
52.1%
-1240%
WATCHLIST
NGLFINE
Small
NGL Fine-Chem Limited
Pharmaceuticals
match 143
38
32.3
17.4%
-339%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Saroja Pharma Industries India Ltd. operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
68Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 56th percentile of the scored universe and 43rd percentile within Pharma. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
56th percentile
overall median 67 · Pharma: 43rd pctile, median 70 · SME: 70th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
65
acceptable · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
88
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 73%.
- ▸Promoter pledge is zero.
- ▸3/4 latest quarters had positive YoY revenue growth.
- ▸3/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸Only 0 years of positive FCF.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Saroja Pharma Industries India Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.